安特里斯科技
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Devices
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 安特里斯科技 (AVR) | 589.62M | -3.10 | 2.35 | 0.00% |
| Abbott Laboratories (ABT) | 181.50B | 33.94 | 3.55 | 2.33% |
| Medtronic (MDT) | 121.20B | 23.34 | 2.41 | 3.01% |
| Stryker Corp (SYK) | 113.02B | 30.53 | 4.71 | 1.18% |
| Boston Scientific (BSX) | 64.33B | 17.97 | 2.58 | 0.00% |
| Edwards Lifesciences (EW) | 49.92B | 50.35 | 4.70 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算28.1%。
合理价值
Anteris Technologies Global Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $7.75 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's balance sheet increases our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 14.2 lies in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.
Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, a core component of profitability, sits in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
经济护城河
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
安特里斯科技 讨论区 0 条评论